Survival of standard risk (SR) patients with ML-DS on AAML1531. (A) The observed 2-year EFS for SR patients (treated without HD-AraC) was 85.6% (95% CI, 75.7-95.5) on AAAML1531 compared with 93.5% for patients who were MRD⁻ at the end of induction course I but whose treatment on study AAML0431 had included HD-AraC. (B) 2-year OS (95% CI) for SR patients on AAML1531 was 91.0% (83.8-95.0) compared with 96.8% (91.6-98.8) for MRD⁻ patients on AAML0431.